Navigation Links
LaunchBio's Invest in Cures Forum February 13 Offers Insights, Connections into Impact Investing in Healthcare

LaunchBio, Inc., a nonprofit organization that identifies, counsels, and supports high-growth, high-impact life science and biotechnology companies, announced today that it will host a forum with investment professionals representing 10 national nonprofit disease foundations and disease-focused venture funds to discuss their investment philosophies, explain their fund and deal structures, and describe how they are using scientific knowledge to validate early stage technologies and syndicate with other investors.

The program, called Invest in Cures, is scheduled for February 13 from 8 a.m. - noon at the New York Stem Cell Foundation, one of the presenting partners for the forum. BioLabs and BioLabs@NYULangone, a premier co-working space for life science innovators, also are joining LaunchBio as presenting partners for this event.

Nonprofit foundations and impact funds increasingly are making investments in life science companies to accelerate the pace of drug discovery and development, hoping to bring new therapies and cures for patients. No longer solely focused on making grants to researchers, disease foundations are creating a range of investment vehicles to achieve their missions.

“We are interested in new sources of capital for early stage life science companies, and see non-traditional investors, such as these foundations, as an important addition to the network,” says Joan Siefert Rose, CEO of LaunchBio. “As disease foundations start venture arms and add investment professionals to their teams, the organizations hosting this forum want to make sure they are meeting other investors and learning about promising companies.”

The confirmed speakers for the forum are:

Jonathan Behr, PhD
Managing Director
T1D Fund, Juvenile Diabetes Research Foundation
Michele Cleary, PhD
The Mark Foundation for Cancer Research

Bob Crutchfield
Managing Director, BrightEdge Ventures
American Cancer Society

Anka K. Ehrhardt, PhD
Science Director
CHDI Management, Inc.

Lauren Friedman, PhD
Director, Scientific Affairs
Alzheimer’s Drug Discovery Foundation

Gerard Honig, PhD
Translational Research Manager
IBD Ventures, Crohn’s & Colitis Foundation
Ken LaMontagne, PhD, MBA
VP, Research, Therapy Acceleration Program
The Leukemia & Lymphoma Society

Debra Miller
President & CEO
Barbara Tate, PhD
Venture Partner
Dementia Discovery Fund
Ben Yerxa, PhD
Foundation Fighting Blindness

The moderators for the forum are:

Michael J. Hostetler, PhD., Esq.
Partner, Intellectual Property
Wilson Sonsini Goodrich & Rosati

Kirstie Keller, PhD
Senior Associate, Center for Strategic Philanthropy
Milken Institute

Robert J. Schneider, PhD
Associate Dean, NYU Technology Ventures and Partnerships, Albert B. Sabin Professor of Molecular Pathogenesis, NYU School of Medicine
NYU Langone Health

Opening remarks will be delivered by:

Adam Milne
VP Operations

Nishta Rao, MBA
Site Director
Elizabeth Schwarzbach, PhD
VP, Business Development
New York Stem Cell Foundation

The Invest in Cures forum is LaunchBio’s first program in New York designed for the biotech community.

Information and registration are available at

About LaunchBio: LaunchBio is a nonprofit organization that identifies, counsels, and supports high-growth, high-impact life science and biotechnology companies. Its mission is to build an ecosystem of innovation for the benefit of human health and well-being.
LaunchBio’s impact is measured by its success in connecting entrepreneurs with knowledge, capital and talent – including each other – not only within geographic regions, but across the nation’s leading life science hubs. LaunchBio offers programs in Durham, NC; San Diego, CA; Boston, MA; and New York City.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. OGIs investment in cytognomix contributes to the Shannon Human Splicing Pipelines success
2. Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator
3. St. Jude scientist named Howard Hughes Medical Institute investigator
4. NYU Langone Medical Center researcher named Howard Hughes Investigator
5. Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter
6. Investigators link poultry contamination on farm and at processing plant
7. Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
8. Bert L. & N. Kuggie Vallee Foundation announces first recipients of its Young Investigator Awards
9. Study investigates extraordinary trout with tolerance to heavily polluted water
10. Global investigation reveals true scale of ocean warming
11. Advances in temporal forensic investigations
Post Your Comments:
(Date:4/4/2019)... ... 2019 , ... Orbsen Therapeutics, a biotechnology company focused on ... move its base of operations from the National University of Ireland (NUI) Galway ... in Galway, Ireland. , “With four clinical trials in full swing and the ...
(Date:4/4/2019)... ... 03, 2019 , ... R3 Stem Cell is now offering ... of Excellence. R3 wants patients to feel secure when they make a significant ... Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a safe ...
(Date:3/29/2019)... (PRWEB) , ... March 28, 2019 , ... In the ... not directly prescribe a path for this task. Despite this uncertainty, several manufacturers have ... of today. In the first part of this webinar, learn how analytical similarity is ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & Cell ... team, including a new addition to the presidential line of succession, at the ... the Society's leadership team for a three-year term (2019-2021). , All five incoming members ...
(Date:4/8/2019)... ... 08, 2019 , ... US Capital Global Securities , an affiliate of ... in the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline ... hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. In phase ...
(Date:4/4/2019)... ... 2019 , ... Biomeme, Inc. , a leading manufacturer ... solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called Franklin ™. ... an English chemist and X-ray crystallographer who made significant contributions to the understanding ...
Breaking Biology Technology: